KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.

Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami

J Eur Acad Dermatol Venereol 40(6) 994-1004

PMID41297955
PMCIDPMC13206257
DOI10.1111/jdv.70166
发表日期2025-11-26
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Palmoplantar pustulosis (PPP) is a difficult-to-treat chronic dermatitis with limited treatment options. OBJECTIVES: To report results from a Phase 3 study of apremilast in patients with moderate to severe PPP (NCT05174065). METHODS: In this randomized, placebo-controlled, double-blind, confirmatory study, Japanese adults with PPP Area and Severity Index (PPPASI) total score ≥12, PPPASI pustules/vesicles severity score ≥2 and inadequate response to topicals were randomly assigned (1:1) to apremilast or placebo for 16 weeks, followed by an active treatment phase where all patients received apremilast through Week 52. The primary endpoint was a ≥50% reduction in PPPASI total score (PPPASI-50) at Week 16, evaluated in all randomized patients. Safety outcomes were assessed in all patients who received ≥1 dose of the study drug. RESULTS: Between March 8, 2022 to April 28, 2023, 176 patients (141 [80%] women, 35 [20%] men) were randomly assigned to apremilast (n = 88 [50%]) or placebo (n = 88 [50%]). Mean (SD) PPPASI total score at baseline was 22.1 (8.1) in the apremilast group and 22.0 (8.4) in the placebo group. A significantly greater proportion of patients achieved PPPASI-50 at Week 16 with apremilast versus placebo (60 of 88 [68%] vs. 31 of 88 [35%]; treatment difference: 32.6% [95% CI: 18.7, 46.5], p < 0.0001). Improvements were maintained through Week 52. The most common adverse events (≥10% of patients) during the double-blind phase in patients receiving apremilast were diarrhea (placebo: n = 3 [3%]; apremilast: n = 17 [19%]), feces soft (placebo: n = 1 [1%]; apremilast: n = 15 [17%]), headache (placebo: n = 2 [2%]; apremilast: n = 10 [11%]) and nausea (placebo: n = 1 [1%]; apremilast: n = 10 [11%]). There were no events of depression or fatal adverse events. CONCLUSIONS: In this Phase 3 trial, apremilast was effective in Japanese patients with moderate to severe PPP. Adverse events were consistent with the known safety profile of apremilast. CLINICALTRIALS: gov: NCT05174065.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Patient disposition.*One patient discontinued treatment but completed the study visits of the placebo‐controlled phase and did not enter the extension phase. † Two patients discontinued treatment but completed the study visits of the extension phase. BID, twice daily.
非 KM Figure
FIGURE 2Efficacy outcomes over 52 weeks. (A) PPPASI‐50 response. (B) Mean change from baseline in PPPASI total score. (C) Mean change from baseline in PPSI total score. (D) Mean change from baseline in pruritus VAS. (E) Mean change from baseline in pain/discomfort VAS. (F) Mean change from baseline in DLQI. Analyzed in the ITT population. For PPPASI‐50, error bars are 95% CI. For PPPASI‐50 (A), NRI was used for missing data; patients who discontinued the study drug due to lack of efficacy/adverse event or use of protocol‐prohibited medication (defined as an IE) were considered nonresponders at time of the IE through end of study, regardless of the observed data. For all other endpoints (B‐F), LOCF was used for missing data; for patients with an IE, data from time of the IE through end of study were imputed from the baseline value, regardless of the observed data. DLQI, Dermatology Life Quality Index; IE, intercurrent event; ITT, intent‐to‐treat; LOCF, last observation carried forward; NRI, nonresponder imputation; PPPASI, Palmoplantar Pustulosis Area and Severity Index; PPPASI‐50, ≥50% reduction from baseline in PPPASI; PPSI, Palmoplantar Pustulosis Severity Index; SE, standard error; VAS, visual analog scale. *Nominal p = 0.0003. † Nominal p < 0.0001.
非 KM Figure
FIGURE 3PPPASI‐50 response rates at Week 16 by baseline demographic and disease characteristic subgroups. ITT population. MI was used for missing data; patients who discontinued the study drug due to lack of efficacy/adverse event or use of protocol‐prohibited medication (defined as an IE) were considered nonresponders at time of the IE through end of study, regardless of the observed data. Based on the Cochran–Mantel–Haenszel method adjusting for the stratification factors of rounded PPPASI total score (≤20, 21 to 30, ≥31) at baseline and focal infection status (yes/no) at baseline. The adjusted difference in proportion is the weighted average of the treatment differences across strata. Two‐sided 95% CI for adjusted difference in proportion is based on a normal approximation to the weighted average. BMI, body mass index; CI, confidence interval; DMARD, disease‐modifying antirheumatic drug; IE, intercurrent event; ITT, intent to treat; MI, multiple imputation; NE, not evaluable; PAO, pustulotic arthro‐osteitis; PGA, Physician's Global Assessment; PPP, palmoplantar pustulosis; PPPASI, Palmoplantar Pustulosis Area and Severity Index.
非 KM Figure